|
|
|
|
| LEADER |
01691nam a2200265 u 4500 |
| 001 |
EB001872359 |
| 003 |
EBX01000000000000001035730 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Cardiac resynchronization therapy (CRT) in chronic heart failure
|h Elektronische Ressource
|
| 260 |
|
|
|a Stockholm, Sweden
|b SBU-Swedish Council on Health Technology Assessment
|c 2007, [2007]
|
| 300 |
|
|
|a 1 PDF file (3 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Heart Failure / therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Cardiac Resynchronization Therapy
|
| 710 |
2 |
|
|a Statens beredning för medicinsk utvärdering (Sweden)
|
| 740 |
0 |
2 |
|a Pacemaker för synkronisering av hjärtkamrarnas rytm (CRT) vid kronisk hjärtsvikt
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a SBU alert report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK447985
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a Conclusions Reduced symptoms (moderately strong scientific evidence), improved quality of life (strong scientific evidence), and improvement in the severity level of disease (strong scientific evidence) were found in comparing cardiac resynchronization therapy (CRT) against pharmacotherapy (strong scientific evidence) alone. Furthermore, the results from 2 trials with followup after 12 months showed some reduction in the mortality risk for CRT compared to pharmacotherapy (strong scientific evidence). The scientific evidence is insufficient to determine the long-term effects and cost effectiveness of the method
|